Quantinuum to report first post-IPO earnings Aug. 11

Quantinuum (QNT) reports its first post-IPO quarterly results Aug. 11 after the close, with consensus expecting a $0.26 loss per share on $7.8 million revenue.

Needham initiated coverage with a Buy rating and a $100 price target, citing the company's long-term commercial opportunity as it advances toward its Apollo fault-tolerant quantum system in 2029. Jefferies also rates the stock a Buy with a $90 target, calling the planned Apollo system a potential industry "commercial tipping point."

The report will offer Wall Street its first look at Quantinuum's commercialization progress since the company priced an upsized initial public offering of 28 million shares at $60 on June 3, raising about $1.68 billion. Shares began trading on the Nasdaq on June 4 and opened at $68, about 13 percent above the IPO price. The stock has slipped 23.9 percent over the past month on post-IPO profit-taking but has rebounded 19.84 percent over the past five sessions, including an 8.25 percent intraday rally on Aug. 3 and a 4.47 percent advance on Aug. 4.

Quantinuum, formed through the merger of Honeywell Quantum Solutions and Cambridge Quantum, generated $30.9 million in 2025 revenue, up 34.4 percent from $23 million in 2024. First-quarter 2026 revenue came in at $5.2 million, down from $19.1 million a year earlier, reflecting the absence of a $16.5 million sales-type lease recognized upfront in the first quarter of 2025. Full-year 2025 bookings totaled $79.3 million, while remaining performance obligations stood at $76.8 million as of March 31.

The company remains firmly in investment mode, posting a $192.6 million net loss in 2025, wider than the $144.1 million loss in 2024. First-quarter research and development expenses rose 53 percent year over year to $54.7 million, while sales and marketing costs climbed to $13.7 million from $3.4 million. Quantinuum used $62.9 million of cash in operating activities and $22.7 million for capital expenditures in the first quarter, ending March with $677 million in cash before receiving IPO proceeds.

The stock trades at 111.85 times forward sales, a premium to industry peers, and carries a market capitalization of $15.17 billion. Of 14 analysts covering the stock, 11 recommend a Strong Buy, one a Moderate Buy and two a Hold. The average price target of $98.75 implies 73.8 percent upside, while the Street-high target of $155 suggests 172.7 percent upside.

The report will test whether Quantinuum can justify its premium valuation as revenue remains small relative to its public-market value. Investors will watch bookings, customer adoption of the Helios system launched late last year with customers including Amgen, BMW Group, JPMorgan Chase and SoftBank, and management's outlook for the remainder of the year.

This article is for informational purposes only and does not constitute investment advice.